Clinical Trial Search

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration — 9; 4; 13; 10 Participants

Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants

Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants

Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants

Primary: Mortality — 93; 61; 52; 84 deaths

Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA)…

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Mortality — 13; 8 Participants

Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants

Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68

Primary: Frequency of SAEs After First Dose of MVA-BN Vaccine — 0 Participants

Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants

Primary: Rate of Completion — 7 Participants

Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples

Primary: Plasma MBL Level (ug/ml) — 717; 1717 ug/l — p=<0.001

Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants

Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants

Primary: Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells — 0.58 Log-10 copies/10^6…

Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs

Primary: Dose Limiting Toxicity — 0; 0 participants with DLTs

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants

Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…

Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants